Direct Acting Antiviral-Post Authorization Safety Study

Completed

Conditions studied: Hepatitis C, Hepatocellular Carcinoma

In brief

This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients following successful HCC treatment interventions.

Key facts

Study ID
NCT03707080
Run by
Target PharmaSolutions, Inc.
People needed
42
Starts
2018-03-09
Expected to finish
2021-06-30
Last updated by the study team
2021-07-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.